Mt Sinais Ichan School of Medicine Has the Art and Science of Medicine

Seventeen renowned faculty members at the Icahn School of Medicine at Mount Sinai have been honored with Mount Sinai's 2021 endowed professorships for their dedication to excellence in research, education, and clinical intendance. They are:

Oren J. Becher, MD

Oren J. Becher, Md, Steven Ravitch Chair in Pediatric Hematology

Oren J. Becher, MD, is the Chief of the Jack Martin Division of Pediatric Hematology-Oncology at Mount Sinai Kravis Children'due south Hospital and Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai. Dr. Becher is a doctor-scientist focused on improving the standard of intendance for children with encephalon tumors, particularly diffuse intrinsic pontine glioma—or, DIPG—an incurable pediatric encephalon cancer. He joined Mount Sinai in 2021 from the Northwestern University School of Medicine where in addition to appointments in the Section of Pediatrics and the Department of Biochemistry and Molecular Genetics, he also maintained clinical responsibilities at Ann & Robert H. Lurie Children'due south Infirmary of Chicago.

By studying the function of the genetic alterations present in DIPG, Dr. Becher'southward laboratory co-discovered the presence of somatic activating mutations in a cistron not previously implicated in cancer, called ACVR1 or ALK2, in 25 percent of children with DIPG, and subsequently developed genetically engineered mouse models that recapitulate the genetic alterations of the human illness. Additionally, Dr. Becher's laboratory has expanded efforts to develop models for other pediatric encephalon cancer subtypes, using these models to report the tumor microenvironment and to evaluate novel therapeutics that help prioritize clinical trials for children with DIPG.

Dr. Becher obtained his Bachelor of Arts degree from the University of Pennsylvania and his medical caste from Johns Hopkins School of Medicine. He completed his pediatric residency at the Children's National Medical Center in Washington, D.C. and fellowships in pediatric hematology-oncology and neuro-oncology at Memorial Sloan Kettering Cancer Center.

Supinda Bunyavanich, MD, MPH, MPhil

Supinda Bunyavanich, MD, MPH, MPhil, Mount Sinai Professor in Allergy and Systems Biology

Bunyavanich, MD, MPH, MPhil is a Professor of Pediatrics and Professor of Genetics and Genomic Sciences at the Icahn Schoolhouse of Medicine at Mount Sinai. Dr. Bunyavanich is also a practicing allergist and immunologist and the Associate Director of the Jaffe Food Allergy Constitute.

Dr. Bunyavanich's inquiry, funded by the National Institutes of Wellness (NIH), combines tools in epidemiology, multi-omics, and systems biological science to elucidate and understand the pathobiology of asthma and allergic diseases. Her research grouping works with homo cohorts to identify risk factors, mechanisms, and potential therapies for these disorders using data science and integrative -omics approaches. Findings from her lab include the identification of a nasal biomarker of asthma past car learning analyses of nasal transcriptome data, label of the airway and gut microbiomes in asthma and food allergy, and identification of master regulator genes of peanut allergy and asthma.

In improver to directing a research group at Mount Sinai, Dr. Bunyavanich provides patient care as a clinical allergist and immunologist, teaches medical and graduate students, and mentors pre- and post-doctoral trainees. She has mentored more than 70 trainees who take gone on to graduate and medical schoolhouse and faculty positions. Dr. Bunyavanich is a frequent invited speaker at national and international meetings, and serves as a grant reviewer and on advisory groups for the NIH. Dr. Bunyavanich received the Harvard Medical Schoolhouse Shore Honor for Scholars in Medicine and is recognized as a Castle Connelly Exceptional Woman in Medicine.

Dr. Bunyavanich earned her undergraduate degree from Harvard University, Doc from Harvard Medical School, MPH from the Harvard School of Public Wellness, and MPhil from the University of Cambridge. She completed her internal medicine residency at Massachusetts General Hospital-Harvard Medical School, her allergy and immunology fellowship at Brigham & Women's Infirmary-Harvard Medical School, and her postdoctoral inquiry fellowship at the Channing Sectionalization of Network Medicine, Brigham & Women's Infirmary-Harvard Medical School.

Kirk North. Campbell, Doc

Kirk Northward. Campbell, Physician, Irene and Dr. Arthur Thousand. Fishberg Professor of Medicine

Kirk N. Campbell, Md, is Associate Professor of Medicine (Nephrology), Vice Chair for Diversity and Inclusion, and Director of the Nephrology Fellowship Program at the Icahn School of Medicine at Mount Sinai. Dr. Campbell is a physician-scientist working to characterize novel pathways in kidney podocyte injury and survival. His clinical interest is in man glomerular disease.

In addition to treating patients, Dr. Campbell advances the understanding of the underlying mechanisms of glomerular illness progression while identifying potential targets for therapeutic intervention. He leads an NIH-funded research program focused on podocyte cell biology, experimental glomerular disease, and clinical trials in the rare kidney disease infinite. Key findings include the identification of dendrin and the Hippo pathways target Yeah-associated protein (YAP) as regulators of podocyte survival and plasminogen as a targetable biomarker in glomerular disease. Dr. Campbell has been a main investigator for clinical trials testing the safety and efficacy of agents in evolution for focal segmental glomerulosclerosis, IgA nephropathy, membranous nephropathy, and lupus nephritis.

Dr. Campbell received his medical degree from the University of Connecticut and completed his internal medicine residency at Yale University earlier conducting clinical and research training in nephrology at Mountain Sinai. He is an elected member of the American Society for Clinical Investigation, Past-President of the New York Society of Nephrology, a member of the Board of Directors of the Nephcure Foundation, and a continuing member of the Pathobiology of Kidney Disease study section at the National Institutes of Health. Dr. Campbell also serves on the Medical Advisory Board of the National Kidney Foundation of Greater New York, and is a fellow member of the American Society of Nephrology's grants review and kidney calendar week teaching committees.

Kecia N. Carroll, MD, MPH

Kecia North. Carroll, Medico, MPH, Debra and Leon Black Professor in Pediatrics

Kecia N. Carroll, MD, MPH, is Chief of the Partitioning of Full general Pediatrics, Professor of Pediatrics, and Environmental Medicine and Public Health at the Icahn School of Medicine at Mount Sinai. Dr. Carroll is a board-certified general pediatrician, clinical investigator, and epidemiologist. She joined Mountain Sinai in 2021 from Vanderbilt Academy Medical Heart, where in improver to a faculty appointment in the Department of Pediatrics, she too served as the Director of Faculty Inclusion and Diversity in the Pediatric Office of Faculty Development, and Chair of the Diverseness Committee for the Primary of Public Health programme.

While at Vanderbilt, Dr. Carroll spearheaded efforts to foster an inclusive environs and created mentoring and career development opportunities for faculty, trainees, and students. She serves as a mentor for faculty and trainees across various career stages and bookish tracks. Through her K24 Midcareer Investigator Award funded by the National Center, Lung & Claret Plant through the National Institutes of Wellness, she mentors early career investigators and contributes to efforts supporting research mentor training.

Dr. Carroll's electric current NIH-funded inquiry plan investigates how environmental exposures—including stress, nutritional exposures, and ecology toxicants—during critical periods of development influence babyhood asthma risk, with a focus on potential modifiable run a risk factors. At Mount Sinai, she collaborates with investigators across the Wellness Arrangement, including within the Institute for Exposomic Enquiry.

Dr. Carroll obtained her Bachelor of Arts degree from Vassar College and her medical degree from Vanderbilt University School of Medicine. She completed her pediatric residency at the University of California San Francisco and a general academic pediatrics research fellowship at Vanderbilt.

Jaime Chu, Doctor

Jaime Chu, Doctor, Mountain Sinai Professor in Pediatric Liver Enquiry

Jaime Chu, Dr., is the Associate Chief of the Division of Pediatric Hepatology, Medical Director of Pediatric Liver Transplantation, and Director of the Pediatric Dr.-Scientist Residency Program at Mount Sinai Kravis Children'southward Hospital and the Recanati/Miller Transplantation Institute at Mount Sinai, where she mentors resident and fellow trainees interested in pursuing a career every bit a md-scientist.

Dr. Chu is a physician-scientist in pediatric hepatology. Her long-term goal is to utilize collaborative science and integrate basic and clinical enquiry towards improving our understanding of the mechanisms underlying pediatric liver illness and to employ this noesis towards the evolution of much needed therapeutic options for children with liver disease.

She is the Director of the Molecular Liver Physiology and Metabolism Lab, where she leads a basic research grouping that focuses on how carbohydrate metabolism pathways work together to regulate liver development and illness. Dr. Chu'south squad capitalizes on the force of the zebrafish as a tool to investigate metabolic mechanisms of liver fibrosis and test potential anti-fibrotic therapies.

Dr. Chu's clinical research includes participation as site Principal Investigator and Co-Investigator in NIH-funded consortia, including a U01-funded project in pediatric acute liver failure and other industry-sponsored pediatric drug trials for genetic cholestatic liver affliction, biliary atresia, and viral hepatitis. Her research has been awarded the Gilead Sciences Research Scholars Liver Disease Award, American Association for the Written report of Liver Diseases (AASLD) Foundation Bridge Honour, and funding from the National Institutes of Wellness (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to examine the part of mannose metabolism in liver fibrosis. Dr. Chu is a member of the NIDDK Study Section for Fellowship Awards and was selected to serve as a member of the AASLD Job Force on COVID-19.

She received her BA magna cum laude from Harvard Academy and her MD from New York Academy School of Medicine. She completed her General Pediatrics residency grooming at Northwestern University/Children's Memorial Hospital (at present Lurie Children'south Hospital of Chicago) and her fellowship in Pediatric Gastroenterology, Hepatology, and Nutrition both at Children's Memorial Infirmary and at the Mount Sinai Schoolhouse of Medicine.

Kristen Dams-O'Connor, PhD

Kristen Dams-O'Connor, PhD, Jack Nash Professor of Rehabilitation Medicine

Kristen Dams-O'Connor, PhD, is Manager of the Encephalon Injury Inquiry Center of Mountain Sinai and Professor in the Departments of Rehabilitation Medicine and Neurology at the Icahn School of Medicine at Mount Sinai.

Dr. Dams-O'Connor conducts multidisciplinary research defended to improving the lives of people living with encephalon injury. Her piece of work aims to identify mechanisms, risk, and protective factors to amend long-term outcomes in individuals with traumatic encephalon injury (TBI) and repetitive head trauma sustained through sports participation, military service, and intimate partner violence. Her squad uses modern psychometric and statistical techniques to measure individual differences in trajectories of alter over time among survivors of TBI. One goal of this work is to amend diagnosis of secondary mail-traumatic weather condition during life so they can be treated.

Dr. Dams-O'Connor also leads the Late Effects of TBI Project, a TBI encephalon donor plan focused on characterizing the clinical phenotype and postmortem pathological signatures of mail-traumatic neurodegeneration and their associations with Alzheimer'due south affliction and related dementias. She is Projection Manager of the New York Traumatic Brain Injury Model Arrangement of Care, one of 16 centers of excellence for TBI research and clinical intendance in the Us.

Her inquiry is supported by federal grants from the National Institutes of Health, the National Institute on Disability, Contained Living, and Rehabilitation Research, the United states of america Department of Defence, the Centers for Disease Command and Prevention, and the Patient-Centered Outcomes Research Institute. Dr. Dams-O'Connor has published more than 150 manuscripts and chapters on TBI treatments and outcomes, and has presented her research internationally.

Thomas J. Fuchs, Dr.sc.

Thomas J. Fuchs, Physiciansc., Mount Sinai Chair in Artificial Intelligence and Human Health

Thomas J. Fuchs, Docsc. is a scientist in the groundbreaking field of computational pathology, focused on the use of artificial intelligence (AI) to analyze images of tissue samples to identify affliction, recommend treatment, and predict result. In October 2020, he was appointed Co-Manager of the Hasso Plattner Institute for Digital Health at Mount Sinai, Dean of Artificial Intelligence and Human Health, and Professor of Computational Pathology and Computer Science at the Icahn School of Medicine at Mount Sinai. In this function, Dr. Fuchs leads the next generation of scientists and clinicians using artificial intelligence and car learning to develop novel diagnostics and treatments for acute and chronic disease.

Dr. Fuchs's work includes developing novel methods for assay of digital microscopy slides to meliorate understand genetic mutations and their influence on changes in tissues. He has been recognized for developing big-scale systems for mapping the pathology, origins, and progress of cancer. This breakthrough was achieved by building a high-performance compute cluster to train deep neural networks at petabyte scale.

Before joining Mount Sinai, Dr. Fuchs was Director of the Warren Alpert Center for Digital and Computational Pathology at Memorial Sloan Kettering Cancer Eye (MSK) and Associate Professor at Weill Cornell Graduate Schoolhouse for Medical Sciences. At MSK, he led a laboratory focused on computational pathology and medical machine learning. Dr. Fuchs besides co-founded Paige.AI in 2017 and led its initial growth to the leading AI visitor in pathology. He is a one-time research technologist at NASA's Jet Propulsion Laboratory and visiting scientist at the California Institute of Engineering science. Dr. Fuchs holds a Doctor of Science in Automobile Learning from ETH Zurich and a MS in Technical Mathematics from Graz Technical University in Republic of austria.

Alison M. Goate, DPhil

Alison Grand. Goate, DPhil,Jean C. and James W. Crystal Professor and Chair of Genomics

Alison M. Goate, DPhil, is the Jean C and James W. Crystal Professor of Genomics and Chair of the Section of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. She has worked on the genetics of neurodegenerative diseases including Alzheimer's affliction (Advertising) and Frontotemporal Dementia (FTD) since 1987, and is the founding director of the Ronald M. Loeb Center for Alzheimer's Disease at Mount Sinai.

Over the last iii decades, Dr. Goate has been part of many cistron finding teams that have successfully identified disease-causing variants for both AD and FTD. While working at Imperial College in London, she reported the first mutation to crusade familial Alzheimer's affliction, and her early on studies at Washington University in St. Louis identified a genetic mutation in Colombian families that are now part of the Alzheimer'south Prevention Initiative clinical trial. Her lab was besides office of the squad that first reported MAPT mutations in FTD.

Dr. Goate is besides a leader in the report of belatedly onset AD genetics using integrative genomic approaches to place novel genetic risk factors. Her work led to the identification of Trem2 as a chance factor for AD and has highlighted the enrichment of AD take a chance variants in microglial enhancers, regulatory elements in Deoxyribonucleic acid that control gene expression in immune cells of the brain. Dr. Goate is now building upon these insights using genome editing in induced pluripotent stem cells to empathize the molecular mechanisms of disease and to develop novel therapeutics.

Dr. Goate has received the Potamkin Award, the Khalid Iqbal Lifetime Achievement Honour from the Alzheimer's Clan, and the MetLife Award for her research on Advertizing. She was elected a boyfriend of the American Association for the Advancement of Science in 2012, and a fellow of the National Academy of Medicine in 2016.

Rita Z. Goldstein, PhD

Rita Z. Goldstein, PhD, Mount Sinai Professor in Neuroimaging of Addiction

Rita Z. Goldstein, PhD, is a Professor of Psychiatry with a secondary date in the Department of Neuroscience at the Icahn School of Medicine at Mount Sinai. Dr. Goldstein is Principal of the Neuropsychoimaging of Addiction and Related Conditions research grouping.

Nationally and internationally known for her neuroimaging and neuropsychological studies in drug addiction, Dr. Goldstein formulated a theoretical model known as Dumb Response Inhibition and Salience Attribution (iRISA). Multiple neuroimaging modalities—including MRI, EEG/ERP, PET—and neuropsychological tests are used to explore the neurobiological underpinnings of iRISA in drug habit and related conditions. This model has fatigued considerable scientific attention (exceeding 2,850 for a review published in the Am J Psychiatry in 2002 and one,970 for another review published in Nature Reviews Neuroscience in 2011). An important application of Dr. Goldstein'southward inquiry is to facilitate the development of intervention modalities that would improve cognitive and emotional function, leading to ameliorate handling outcomes, in drug addiction and other chronically relapsing disorders of self-regulation.

Dr. Goldstein has authored or co-authored more than 145 highly cited, peer-reviewed manuscripts and book chapters focusing on the role of the prefrontal cortex in drug addiction. Her inquiry has been independently funded past several federal and private agencies, with total funding of more than $xx million every bit a principal or multiple investigator or plan director. She became a fellow of the American Higher of Neuropsychopharmacology in 2015, receiving the prestigious Joel Elkes Research Honour in 2012 and the Jacob P. Waletzky Award in 2013.

Mentoring is a high priority for Dr. Goldstein. She has mentored numerous trainees, spanning from postdoctoral fellows to graduate, undergraduate, and high school students. Her trainees have published many first authorship manuscripts in top psychiatry and neuroscience journals, have become primary investigators on their own NIH-funded grants, and many of them are now leading independent research labs at prestigious institutions.

Dr. Goldstein earned an undergraduate degree from Tel Aviv University in Israel. She received her PhD in Health Clinical Psychology from the University of Miami afterwards completing a yearlong internship in clinical neuropsychology at the Long Island Jewish Medical Eye. She and so completed her postdoctoral preparation on brain imaging and alcohol abuse through a fellowship from the National Institutes of Health at Brookhaven National Laboratory.

Emma Guttman-Yassky, MD, PhD

Emma Guttman-Yassky, Medico, PhD, Waldman Chair of Dermatology

Emma Guttman-Yassky, Md, PhD, is the Waldman Professor and System Chair of The Kimberly and Eric J. Waldman Section of Dermatology at the Icahn School of Medicine at Mount Sinai. A earth-renowned dermatologist and physician scientist, Dr. Guttman-Yassky divides her time betwixt a decorated clinic and her laboratory that investigates the mechanisms underlying inflammatory pare diseases, leading to novel treatments for these patients.

Dr. Guttman-Yassky's major clinical and research area of expertise is inflammatory skin diseases, with major focus on eczema/atopic dermatitis (AD) and baldness areata, as well as other inflammatory skin diseases. She made paradigm-shifting discoveries on the immunologic basis of Advert/eczema in humans, opening the door to new therapeutics. Dr. Guttman has developed the only comprehensive molecular maps of AD, defining pare differentiation and allowed-circuits characterizing this disease.

Her research on atopic dermatitis/eczema has contributed to many of the recently developed treatments for this affliction, earning her a unique place as one of the leaders in dermatology and immunology worldwide. She has as well shown that AD is a complex disease with distinct phenotypes based on ethnicity, age, and other factors. She has shown that atopic dermatitis in Asian and African American patients is different from atopic dermatitis in European American patients, with important therapeutic implications. She is now testing (both clinically and mechanistically) multiple targeted-therapeutics for atopic dermatitis. She has recently also extended her inquiry interest to alopecia areata in which her findings are also translated to novel therapeutic targets.

Dr. Guttman-Yassky is considered one of the world's leading experts in inflammatory skin diseases and authored more than 250 manufactures and is often invited equally a keynote and plenary speaker to multiple international and national meetings. She co-founded the International Eczema Council, for which she functions equally immediate by president. This organization now comprises the vast bulk of top experts in atopic dermatitis/eczema worldwide. She is also on the scientific advisory board of the National Eczema Association and the board of the American Peel Clan. She was also elected to the American Society for Clinical Investigation and the American Dermatological Gild, and she has received the Young Investigator Honour from the American Academy of Dermatology, the Bettina C. Hilman, MD Lectureship and Award from the American University of Allergy and Immunology that honors a pioneer in allergy enquiry whose contributions to science and medicine impacted patients' lives, the Donald Y. Grand. Leung, MD, PhD-JACI Editors Lectureship and Faculty Development Accolade, and many other awards.

She earned her Medico from Sackler at the Tel-Aviv University, and a PhD degree from the Bar-Ilan Academy, Israel. After her Israeli Board certification in dermatology in Israel, Dr. Guttman-Yassky moved to the U.Due south. for a postdoctoral fellowship at The Rockefeller University. She so became lath-certified in the U.S. after a 2nd dermatology residency training at Weill Cornell Medical College.

Girish N. Nadkarni, Doc, MPH

Girish N. Nadkarni, Physician, MPH, Irene and Dr. Arthur M. Fishberg Professor of Medicine

Girish Northward. Nadkarni, Doc, MPH, is Associate Professor of Medicine (Nephrology) with tenure at the Icahn Schoolhouse of Medicine at Mountain Sinai. Equally an adept physician-scientist, Dr. Nadkarni bridges the gap between comprehensive clinical care and innovative research. He is the Chief of the Division of Information Driven and Digital Medicine (D3M), the Co-Chair of the Executive Management Team of the Mount Sinai Clinical Intelligence Center (MSCIC), the Clinical Director of the Hasso Plattner Plant for Digital Health at Mount Sinai, likewise as a cadre faculty member in the Charles Bronfman Found for Personalized Medicine.

Before completing his medical degree at i of the top-ranked medical colleges in India, Dr. Nadkarni received preparation in mathematics. He and then received a master's degree in public health at the Johns Hopkins Bloomberg School of Public Health, and then was a inquiry associate at the Johns Hopkins Medical Institute. Dr. Nadkarni completed his residency in internal medicine and his clinical fellowship in nephrology at the Icahn School of Medicine at Mountain Sinai. He then completed a inquiry fellowship in personalized medicine and informatics at the Charles Bronfman Constitute Personalized Medicine, where he was mentored by Dr. Erwin Bottinger.

Dr. Nadkarni has authored more than 200 peer-reviewed scientific publications, including articles in the New England Periodical of Medicine, the Journal of the American Medical Clan, the Annals of Internal Medicine and Nature Medicine. Dr. Nadkarni is the principal or co-investigator for several grants funded by the National Institutes of Wellness focusing on informatics, data science, and precision medicine. He is also one of the multiple main investigators of the NIH RECOVER consortium focusing on the long term sequelae of COVID-19. He has several patents, and is also the scientific co-founder of investor-backed companies—one of which, Renalytix, is listed on NASDAQ. In recognition of his piece of work as an agile clinician and investigator, he has received several awards and honors, including the Dr. Harold and Golden Lamport Inquiry Award and the Deal of the Year Laurels from Mount Sinai Innovation Partners for his work with Renalytix.

Louis R. Pasquale, Physician, FARVO

Louis R. Pasquale, Physician, FARVO, Shelley and Steven Einhorn Distinguished Chair of Ophthalmology

Louis R. Pasquale, Doc, FARVO, joined Mountain Sinai in 2018 as Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai and Site Chair of Ophthalmology at The Mountain Sinai Hospital and Mount Sinai Queens. Prior to joining Mount Sinai, he worked at Massachusetts Eye and Ear, a teaching infirmary of Harvard Medical School, for 25 years. There, he rose to the rank of Professor of Ophthalmology and Distinguished Scholar in Ophthalmology at Harvard Medical School equally well as Director of the Glaucoma Service at Massachusetts Heart and Ear.

With continuous back up from the National Institutes of Wellness since 2006, Dr. Pasquale's research has focused on the discovery of main prevention strategies in open-angle glaucoma. His piece of work has highlighted the role of environmental risk factors for exfoliation syndrome and the importance of nitric oxide signaling in primary open-angle glaucoma. He has besides contributed to resolving the complex genetic compages of chief open-angle glaucoma. His work is highly impactful with more than than 309 publications in PubMed and an h-alphabetize of 68.

Dr. Pasquale is a fellow member of the editorial boards of Ophthalmology Glaucoma, International Glaucoma Review, Asia-Pacific Journal of Ophthalmology, and the American Journal of Ophthalmology. He served as a member of the National Institutes of Health's National Advisory Eye Quango. He is currently the Association for Research in Vision and Ophthalmology (ARVO) Glaucoma Section Trustee and a Aureate Fellow of ARVO. Finally, he is a member of the American Ophthalmological Gild and the Glaucoma Research Society.

Dr. Pasquale earned his medical degree at the State Academy of New York Stony Brook School of Medicine. He completed an internal medicine internship at Bronx Municipal Hospital, an ophthalmology residency at Temple University Hospital, and a two-year fellowship in glaucoma at Johns Hopkins School of Medicine.

Leslee J. Shaw, PhD

Leslee J. Shaw, PhD,Mount Sinai Professor in Women's Health Enquiry

Leslee J. Shaw, PhD, is an internationally recognized cardiovascular outcomes researcher, with a stiff focus on women's health that encompasses quality, equity, and evaluation of cardiovascular diseases such as atherosclerosis in women. Before joining the Icahn School of Medicine at Mountain Sinai in 2021, she directed the Dalio Institute at Weill Cornell Medical Higher. Prior to her fourth dimension at Weill Cornell, Dr. Shaw held the R. Bruce Logue Professorship at the Emory University School of Medicine.

At Mount Sinai, Dr. Shaw holds a triple primary appointment in Medicine (Cardiology), Population Wellness Science and Policy, and Obstetrics, Gynecology and Reproductive Science, and serves equally Director of The Blavatnik Family Women'southward Health Inquiry Constitute. Through this organization, Dr. Shaw will expand upon the Institute's goals for interdisciplinary collaboration in women's health, and her strong commitment to mentoring and faculty development will heighten collaboration with inferior faculty inside the Institute.

Dr. Shaw has published more than than 760 publications and presented more than 400 abstracts in major scientific meetings in the United States, Europe, Asia, and South America. She has been ranked for more than a decade as i of the elevation 1 percent of clinical researchers with the most highly cited publications, awarded by Thomson Reuters. Based on her scientific contributions, Dr. Shaw received from the American Higher of Cardiology the Simon Dack Award for academic excellence in 2009, and, in 2013, the Coalition to Reduce Disparities in Cardiovascular Disease Outcomes Honor for her studies on racial and indigenous differences in cardiovascular illness. Likewise in 2013, she received the Women's Day Red Apparel Award for her scientific contributions to women's health.  Recently, in 2020, Dr. Shaw was awarded the Bernadine Healy Leadership Award in Women's Cardiovascular Disease from the American College of Cardiology, the Nanette Wenger Honor from the American Society of Preventive Cardiology, and the Distinguished Investigator Award from the Academy for Radiology and Biomedical Imaging Research.

Joseph A. Sparano, Physician

Joseph A. Sparano, Md, Ezra M. Greenspan, MD Professor in Clinical Cancer Care Therapeutics

Joseph A. Sparano, MD, an internationally-recognized expert in the direction of chest cancer and HIV-associated malignancies, is Principal of the Division of Hematology and Medical Oncology for the Mount Sinai Health Arrangement and Deputy Director of The Tisch Cancer Institute. Dr. Sparano joined Mountain Sinai in 2021 following a distinguished 33-year career at the Albert Einstein Higher of Medicine and Montefiore Medical Center, where he was Professor of Medicine and Obstetrics & Gynecology and Women'south Health, Associate Chairman for Clinical Research in the Department of Oncology, and Associate Managing director for Clinical Enquiry at the Albert Einstein Cancer Center.

Dr. Sparano led a quantum clinical trial in breast cancer inquiry, the Trial Assigning Individualized Options for Treatment, known as TAILORx—the first and largest National Cancer Institute (NCI) precision medicine trial. It integrated the 21-gene expression assay into clinical decision making for adjuvant therapy of early stage ER-positive, HER2-negative breast cancer. The trial led to changes in treatment guidelines from both the American Society of Clinical Oncology and the National Comprehensive Cancer Network. TAILORx results were published in the New England Periodical of Medicine in 2015, 2018, and 2019. Dr. Sparano too led an attempt to develop and validate a new tool integrating clinical and genomic data to guide adjuvant therapy for breast cancer which became freely available for widespread clinical use after publication in the Periodical of Clinical Oncology in 2021. Evidence generated from another trial that he led which evaluated the office of taxane therapy in early on chest cancer, published in the New England Journal of Medicine in 2008, has also had an important and enduring impact on standard clinical practice guidelines.

Dr. Sparano has conducted impactful studies aimed at improving the outcomes of HIV‐positive patients with cancer, including enquiry on novel approaches for treating non‐Hodgkin lymphoma and anal cancer in individuals with HIV. He has besides focused his research on improving racial disparities in cancer care and on cancer metastasis. Dr. Sparano's enquiry has been funded by the NCI likewise as the Chest Cancer Research Foundation, Susan Thou. Komen Foundation, and V Foundation.

Dr. Sparano is Chair and Primary Investigator of the AIDS Malignancy Consortium, a network of clinical trial sites in the U.Due south., Africa, and Latin America. He serves as Deputy Chair of the Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network Cancer Research Grouping, and is a member of the Board of Managers of the PreECOG Research Foundation and the Early on Breast Cancer Trialists' Collaborative Grouping Steering Committee. He is a recipient of some of the most prestigious awards in the field of medical oncology, including the ECOG Young Investigator Award, the Charles Moertel Laurels and Lecture by the Alliance for Cancer Clinical Trials, the American Association for Cancer Inquiry William L. McGuire Award and Lecture, and the American Social club of Clinical Oncology Gianni Bonadonna Award and Lecture.

Filip 1000. Swirski, PhD

Filip K. Swirski, PhD, Arthur and Janet C. Ross Professor of Medicine

Filip K. Swirski, PhD, is the Arthur and Janet C. Ross Professor of Medicine and Professor of Diagnostic, Molecular and Interventional Radiology also as Director of the Cardiovascular Research Constitute at the Icahn School of Medicine at Mount Sinai. He has secondary appointments at the Precision Immunology Plant and the BioMedical Engineering and Imaging Institute. Dr. Swirski obtained his PhD at McMaster Academy in Hamilton, Canada, and postdoctoral studies at Brigham and Women'southward Hospital in Boston. Dr. Swirski was Professor at Harvard Medical School and Principal Investigator at Massachusetts Full general Infirmary before joining Mount Sinai in 2021.

Dr. Swirski has been recognized nationally and internationally as a leader in the field of innate amnesty and inflammation in illness. He focuses on cardinal and translational cardiovascular scientific discipline within the context of the hematologic, immune, metabolic, and nervous systems, with specific accent on cell evolution, communication, and function. Recently, his piece of work has expanded to include lifestyle factors such every bit sleep, diet, and stress every bit critical modulators of cardiovascular wellness and hematopoiesis.

Dr. Swirski is a highly cited researcher and is the recipient of numerous awards, including the Jeffrey M. Hoeg Award from the American Heart Association, the William Harvey Lecture from the European Society of Cardiology, the Martin Prize for Central Enquiry, and the Howard Yard. Goodman Fellowship, and he was as well the Patricia and Scott Eston Research Scholar at Massachusetts General Hospital. Dr. Swirski has been continuously funded by the National Institutes of Health. He holds an Outstanding Investigator Award from the National Heart, Lung, and Blood Institute, an Established Investigator Award from the American Heart Association, and is the North American Coordinator of a Leducq Foundation Transatlantic Network of Excellence Consortium.

Rachel Yehuda, PhD

Rachel Yehuda, PhD, Mount Sinai Professor in Psychiatry and Neuroscience of Trauma

Rachel Yehuda, PhD, is Professor and Vice Chair of Psychiatry for Veterans Affairs, and Professor of Neuroscience at the Icahn School of Medicine at Mount Sinai. She is also the Mental Health Manager at the Bronx Veterans Diplomacy Medical Center.

A recognized leader in the field of traumatic stress studies, Dr. Yehuda has authored more than 500 papers and received numerous grants and awards in the field of traumatic stress and the neuroscience of post-traumatic stress disorder (PTSD). Throughout her career, her research has focused on the study of the indelible effects of trauma exposure in multiple populations such every bit combat veterans, Holocaust survivors, and victims of 9/11 and interpersonal violence. These studies accept examined the human relationship between the biological and psychological changes associated with trauma.

Dr. Yehuda'south pioneering work has resulted in an understanding of the epigenetic changes associated with trauma and PTSD, and likewise molecular alterations in clan with intergenerational trauma. Dr. Yehuda's laboratory has investigated novel treatment approaches for PTSD and the biological factors that may contribute to differing treatment outcomes for the purpose of developing personalized medicine strategies for treatment matching in PTSD. This work has resulted in an approved U.S. patent for a PTSD claret examination. Her laboratory is as well using advances in stalk cell technology to examine PTSD cistron expression networks in induced neurons. Well-nigh recently, Dr. Yehuda established the Center for Psychedelic Psychotherapy and Trauma Inquiry at Mountain Sinai, which integrates sophisticated encephalon imaging and molecular neuroscience in PTSD with clinical trials using psilocybin and MDMA-assisted psychotherapy and other related medicines.

Bin Zhang, PhD

Bin Zhang, PhD, Willard T.C. Johnson Inquiry Professor of Neurogenetics

Bin Zhang, PhD, is a Professor of Genetics and Genomic Sciences and the Director of the Center for Transformative Disease Modeling at the Icahn School of Medicine at Mountain Sinai. Prior to joining Mount Sinai, Dr. Zhang worked as a Primary Scientist and Group Leader of Network Biology at Sage Bionetworks, a non-profit research system started that grew out of Rosetta Inpharmatics, a wholly owned subsidiary of Merck & Co. Dr. Zhang earned his PhD and a master's degree in Informatics from the State University of New York at Buffalo, a primary's caste in electronic engineering from Tsinghua University, Beijing, China, and a available'south degree in electrical engineering from Tongji University, Shanghai, People's republic of china.

Dr. Zhang's extensive experience in electrical engineering science and figurer scientific discipline empowers him to build highly predictive models for very complex data from handwritten certificate images to large-calibration illness multi-Omics information. His expertise lies in information mining, pattern recognition, and systems biological science. Over the past decade, Dr. Zhang has adult a series of influential cistron network inference algorithms which have been extensively used for identification of novel pathways and gene targets, as well as evolution of drugs for human diseases such every bit cancer, Alzheimer'south, obesity, and diabetes.

Dr. Zhang is leading the effort of integrative multiscale network biology modeling of large-scale multi-Omics data in complex human diseases including cancer, diabetes, low, Parkinson'southward disease, Alzheimer'southward disease, influenza and Zika infection, and COVID-nineteen, also as pollution-induced asthma. Building upon highly robust and predictive mechanistic network models underlying these diseases, he is developing novel therapeutics for these illnesses using the state-of-the-fine art artificial intelligence and auto learning approaches.

A prolific researcher, Dr. Zhang has published 190 papers including a number of loftier profile papers in Nature, Science, Cell, and Nature Genetics. His research on cancer established the starting time prepare of data driven predictive cistron network models and driver genes of molecular alterations in chest cancer, primary melanoma, and gastric cancer. Such effort has been extended to more 30 cancer types. His enquiry on the genetic networks and regulators of Parkinson's disease opens upward a new artery for studying the illness. His research that uncovered an immune/microglia cistron network causally linked to Alzheimer's disease (Ad) was published in Jail cell in 2013 and selected by the Periodical of Alzheimer's Disease every bit one of the pinnacle 50 about influential papers on Advertising published from 2013 to 2017. His subsequent research in this direction further systematically identified molecular signatures underlying selective regional vulnerability to Advertizement and reconstructed neuronal cistron subnetworks dysregulated in AD. More importantly, he recently uncovered three major molecular subtypes of Ad, which are independent of age and disease stage. Novel compounds are beingness developed for targeting the network models and fundamental drivers of Advert. These studies led by Dr. Zhang provide a foundation for determining more effective biomarkers for early prediction of Advertizement, studying causal mechanisms of Advertisement, developing next generation therapeutics for AD, and designing more effective and targeted clinical trials, ultimately leading to precision medicine for Advertising.

sharpwabiagre.blogspot.com

Source: https://health.mountsinai.org/blog/icahn-school-of-medicine-at-mount-sinai-awards-endowed-professorships-for-2021/

Share this post